SEC Form 4 · accession 0001179110-17-004594

ACCELERON PHARMA INC · XLRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 2, 2017

Accepted (ET)

Mar 14, 2017 · 6:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001280600

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 2, 2017	A	1,250	$0.00	A	1,250	D
Common Stock^F1,F2	holding	—	—		—	105,122	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F3	$30.17	Mar 2, 2017	A	7,500	A	—	Mar 2, 2027	Common Stock	7,500	7,500	D

F1Represents 98,674 shares, 3,959 shares, 1,902 shares and 587 shares of common stock held by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C") and ATV Entrepreneurs VII, L.P. ("ATV VII E"), respectively.
F2ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.
F3The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.